Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
The Versatility of Fragment Screening Approaches and the Application of Fragment Binding Information in Durg Discovery
Stefan Geschwindner, AstraZeneca, speaking at Discovery Chemistry Congress 2012.
Date Posted: Friday, November 23, 2012
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

AstraZeneca to Invest in New Biologics Manufacturing Facility
New facility in Södertälje, Sweden, to support accelerating biologics portfolio.
Thursday, May 21, 2015
AstraZeneca and Montreal Heart Institute Partner
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits.
Thursday, May 14, 2015
AstraZeneca and Abbott Partner
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma.
Thursday, May 14, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Forms CRISPR Collaborations
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform.
Thursday, January 29, 2015
AstraZeneca To Expand Its Frederick Biologics Manufacturing Center
$200+ million investment to support company’s maturing biologics pipeline.
Tuesday, November 25, 2014
AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca system implemented with input from Tessella wins 2014 Bio-IT World Best Practices Award
Award winning Clinical & Health IT system allows AstraZeneca to respond rapidly to safety concerns and swiftly identify risk factors for adverse events, protecting trial participants while rescuing trials from costly late-stage failure.
Saturday, May 10, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca to Acquire Pearl Therapeutics to Strengthen Respiratory Portfolio
Pearl Therapeutics is focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Wednesday, June 12, 2013
AstraZeneca to Acquire Omthera Pharmaceuticals
Acquisition includes the take-over of NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio.
Wednesday, May 29, 2013
AstraZeneca and BMS Receive Award from Major Medical Association
Companies received the American College of Endocrinology (ACE) Philanthropic Award at the AACE 22nd Annual Scientific & Clinical Congress in Phoenix, Arizona on May 4, 2013.
Thursday, May 09, 2013
Scientific News
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Scientists Create Mice with a Major Genetic Cause of ALS and FTD
NIH-funded study provides new platform for testing treatments for several neurodegenerative disorders.
New Target for Treating Rheumatoid Arthritis
Many affected individuals still suffer with progressive joint damage, despite treatment. This study has discovered a new treatment target which could open a door to preventing this ongoing damage.
Shining A New Light On The Immune System
Scientists at the University of St Andrews have developed a revolutionary method of identifying cells of the immune system with “molecular fingerprints” which could pave the way for the rapid detection of conditions such as leukaemia and lymphoma from a small blood sample.
Inexpensive Technique Developed to Manufacture Nanofibers
Current methods for producing nanofibers are incredibly costly and therefore limit accessibility, this new study opens the door to cheap, mass produced nanofibers.
Normal Skin Accrues High Number of Mutations Associated with Cancer
Researchers used genomic sequencing to gain insights into how somatic mutations build up in normal cells before the onset of cancer, a process that is poorly understood.
Diversity of the Global Ocean Microbiome
The Tara Oceans Consortium have revealed the huge diversity of species living in the oceans including viruses, prokaryotes and picoeurokaryotes.
Promising Malaria and Dengue Vaccines Will Not Defeat Diseases
Although vaccination is a key part of the control of disease GlobalData stress the importance of a multi-dimensional approach.
Amazing Microdroplet Structures May Lead to New Technologies
Research has unveiled a new method of controlling the shapes of structures—so called mesoatoms—formed by microdroplets placed inside another drop.
Gel Filled with Nanosponges Cleans up MRSA Infections
Nanosponge-hydrogel minimize the growth of skin lesions on MRSA infected mice without the use of antibiotics.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters